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Objective: This study assessed prognostic factors regarding long-term outcome for amputation and death among patients
who underwent intra-arterial thrombolysis due to lower limb ischemia.
Methods: Consecutive patients with intra-arterial thrombolysis due to lower limb ischemia treated at the Department of
Vascular Diseases, University Hospital of Malmö, between January 1, 2001, and December 31, 2005, were retrospec-
tively reviewed. A multivariate Cox regression analysis was performed to determine independent predictors for
amputation and death.
Results: A total of 220 intra-arterial thrombolysis procedures were performed in 195 patients (46% women). Median age
was 73 years. Complete and partial thrombolysis was obtained in 41% and 38%, respectively. Hemorrhagic complications
were documented in 33%, but only 6% (13 of 220) were interrupted. The amputation rate was 26% andmortality was 35%
during a median follow-up of 32 months. Degree of lysis (hazard ratio [HR], 4.8; 95% confidence interval [CI], 2.4-9.7;
P< .001), motor deficit at admission (HR, 4.0; 95% CI, 1.8-8.7; P .001), foot ulcers (HR, 7.2; 95% CI, 2.2-23.4; P
.001), and ischemic heart disease (HR, 2.3; 95% CI, 1.1-4.8; P  .024) remained as independent factors associated with
amputation. Renal insufficiency (HR, 2.4; 95% CI, 1.4-4.2; P .003), ischemic heart disease (HR, 2.1; 95% CI, 1.2-3.7;
P  .007), cerebrovascular disease (HR, 2.2; 95% CI, 1.2-4.0; P  .009), foot ulcers (HR, 3.2; 95% CI, 1.2-8.6; P 
.019), and acute lower limb ischemia (HR, 3.4; 95% CI, 1.1-10.1; P  .028) remained as independent factors associated
with mortality.
Conclusions: Thrombolysis is successful, with fewmajor complications inmost patients with lower limb ischemia. Patients
with ischemic heart disease and foot ulcers are at higher long-term risk for both amputation and death. A lesser degree
of lysis and motor deficit were associated with higher amputation rates. The presence of such negative prognostic factors
may help clinicians to deny further invasive vascular treatment. Renal insufficiency, cerebrovascular disease, and acute
lower limb ischemia were associated with increased mortality. ( J Vasc Surg 2008;47:1243-50.)Patients with advanced vascular disease are increasingly
being treated with endovascular techniques at the expense
of a continuous decline in open surgery.1 Most endovascu-
lar procedures can be performed under local anesthesia,
which makes it possible to treat the most fragile patients.2,3
Parallel to the rapid development of high-resolution imag-
ing techniques, there has also been a clear shift towards
increased diagnostic resources in both magnetic resonance
(MR) and computed tomography (CT) angiographies be-
fore intervention in patients with acute lower limb isch-
emia.
Taken together, imaging-based catheter-directed throm-
bolytic therapy has evolved as the treatment modality of
choice in patients with acute lower limb ischemia in our
department. In contrast with open surgery, the level of
occlusion and cause can be determined in a more detailed
manner, and the locally dissolved clot can be cleared with
less risk of injuring the sensitive underlying endothelium
and occurrence of rethrombosis.4
Nevertheless, the Fogarty balloon-catheter thrombo-
embolectomy device5 may be preferable to use in patients
with motor deficit to be able to rapidly remove the throm-
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doi:10.1016/j.jvs.2008.01.053boembolic material and to achieve early reperfusion of
severe ischemic areas. Thrombolysis can be followed by
endovascular, open, or hybrid treatment, whereas open
surgery seldom can be performed before thrombolysis. The
main aim of the present study was to assess the long-term
prognostic factors associated with leg amputation and
death after local intra-arterial thrombolysis for lower limb
ischemia.
METHODS
Setting. The Vascular Center, Malmö-Lund has a pri-
mary catchment population of approximately 756,000 in-
habitants.6 Patients requiring endovascular interventions,
including intra-arterial thrombolysis, are all relocated to
Malmö. The clinic also serves as a referral center for patients
with complicated vascular disease from other hospitals
within the regions in the southernmost part of Sweden. In
2002, there were 265,000 inhabitants in Malmö (128,000
men; 137,000 women).6
Study population. This study comprised all patients
with lower limb ischemia who underwent intra-arterial
thrombolysis between January 1, 2001, and December 31,
2005. The patients were identified in the prospective data-
base for endovascular intervention. Of the 237 patients
identified, 17 were excluded because of misclassification
(n 2), local thrombolysis in other arterial segments (n 4),
or double registration during the same thrombolysis (n 
1243
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for further analysis.
Local intra-arterial thrombolysis. According to a
local memo,7 the presence of any absolute or relative con-
traindication for thrombolysis is checked. The absolute
contraindications are the following risk factors for bleeding
during thrombolysis: operation or organ biopsy2 weeks,
cerebral infarction 6 weeks, cerebral metastasis, known
arteriovenous cerebral malformations, and epidural cathe-
ter or puncture of the dura 3 days.
A number of predetermined blood tests are taken im-
mediately before thrombolysis, including levels of creati-
nine, hemoglobin, aspartate aminotransferase, alanine ami-
notransferase, bilirubin, lactate dehydrogenase, activated
partial thromboplastin time (APTT), prothrombin com-
plex, and platelet count. A prothrombin complex value
1.5 international normalized ratio (INR) is generally not
accepted before arterial puncture. A patient will not be
treated with thrombolysis if no patient bed is available in
the intensive care unit (ICU).
Any prior MR or CT imaging of the patient’s vascular
tree is scrutinized. Arterial puncture is performed in the
common femoral artery in the nondiseased leg, and a long
thrombolysis catheter, equipped with multiple side holes, is
advanced to the diseased leg and positioned in the occlu-
sion to be able to deposit high concentrations of lytic agent.
Infusion of alteplase (Actilyse; Boehringer Ingelheim,
Stockholm, Sweden), a recombinant tissue plasminogen
activator (rt-PA), commences at the ICU, with repeated
measurements of coagulation status throughout the treat-
ment. Initially, a dosage of 1 to 2 mg/h is administered
during the first 4 hours, followed by 0.5 to 1 mg/h,
depending on the age and extent of the occlusion, the
degree of ischemia, and the patient’s age. Parallel with this,
heparin (Heparin Leo, LEO Pharma, Malmö, Sweden) is
first given as a bolus dosage of 5000 IU and then continu-
ously through the side hole of the introducer, which is
placed with its tip above the occlusion. The heparin infu-
sion is adjusted according to APTT values, which should be
two to three times above the reference value during ther-
apy.
Retrieval of patient data. Apart from prospectively
collected data from the endovascular database, data were
retrieved from patient records at the clinics of emergency
care, internal medicine, surgery, orthopaedics, neurology,
and the ICU. All patients registered in the municipality of
Malmö entered the epidemiology analysis. Results from
MR, CT, and angiography/thrombolysis were scrutinized.
Follow-up. All patients were monitored from the day
of thrombolysis until death or January 24, 2007. Median
follow-up time was 32 months. Information about ampu-
tations was retrieved from case records from the Depart-
ments of Orthopaedics in Malmö-Trelleborg, Lund, Ystad,
Helsingborg, Kristianstad, Karlskrona, Karlshamn, Kalmar,
and Växjö. In addition, a senior orthopedic surgeon pro-
vided us with data from his personal on-going amputation
register in Lund. Four patients lived in cities in the middle
part of Sweden, and their amputation status could not beevaluated, either through denial of medical records or
uncertainties about the follow-up hospital. Follow-upmor-
tality data were retrieved from the Swedish Population
Registry.
The analysis of long-term outcome in terms of leg and
patient survival encompassed all primary amputations and
deaths, respectively, occurring between the date of throm-
bolysis and end of follow-up. The causes of deaths were
obtained from the National Board of Health and Welfare.
Information onmortality was not possible to achieve in one
patient living in the United States. This study was approved
by the Research Ethics Committee at the University of
Lund.
Definitions. Hypertension was defined as systolic
blood pressure 140 mm Hg or diastolic blood pressure
90 mm Hg, or both, on at least two different occasions.
Hypertension was also considered if the patient previously
had been diagnosed with hypertension or was taking anti-
hypertensive medication. Cerebrovascular disease was con-
sidered if there was a history of stroke (cerebral bleeding or
infarction) or transient ischemic attack (TIA). Other vascu-
lar disease was present if the patient had any history of
ischemic heart disease, cerebrovascular disease, or aortic
aneurysm or dissection. This definition also included pa-
tients who received antiplatelet drugs or lipid-lowering
agents. Ischemic heart disease was considered if there was a
history of myocardial infarction, angina pectoris, coronary
artery bypass graft, or percutaneous coronary angioplasty.
Diabetes mellitus was noted if the patient had antidiabetic
treatment with diet, oral hypoglycemic agents, or insulin.
Smoking included both current and former tobacco smok-
ers. Hemoglobin (Hb) and creatinine levels at admission
were analyzed. Anemia was defined as Hb 134 g/L in
men and 117 g/L in women, and renal insufficiency was
present if serum creatinine reached levels105 mol/L in
men and 90 mol/L in women.
Acute ischemia in the lower limb was defined as a
sudden decrease in or deterioration of limb perfusion caus-
ing a potential threat to viability of the extremity.8 Dura-
tion of symptom was counted in hours from the time of
onset to the start of thrombolysis. Degree of lysis was stated
as complete, partial, lysis but no run-off, or no lysis.9
Complementary procedures after thrombolysis were
defined as endovascular (aspiration of thromboembolic
material, percutaneous transluminal angioplasty, stenting),
open (bypass grafting, thromboembolectomy, thromboen-
darterectomy, other vascular reconstruction), or hybrid
(endovascular and open) interventions.
Statistical methods. Data management and statistical
analysis were performed using SPSS 14.0 software (SPSS
Inc, Chicago, Ill). Total and sex-specific incidence rates of
thrombolysis were determined by the number of thrombol-
ysis and were expressed as number of cases per 100,000
person-years. The 2002 Malmö population was used as
reference population. Confidence intervals (CI) were cal-
culated from the formula for normal approximation (n 
1.96 n). Differences in proportions were evaluated using
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of lysis, the Kendall -b test was used.
Age, ankle-brachial pressure index, duration of symp-
toms and thrombolysis, and total dosage of alteplase and
heparin were expressed as median and interquartile range
(IQR), and comparisons between groups were made with
the Mann-Whitney U test. Leg and patient survival was
analyzed according to the Kaplan-Meier method. Variables
associated with amputation or death during follow-up were
further tested in a multivariate Cox regression model, with
all variables entered into the model. Significant associations
were expressed in terms of hazard ratios (HR) with 95% CI;
and P  0.05 was considered significant.
RESULTS
Incidence of thrombolysis. During the 5-year study
period, 220 intra-arterial thrombolytic interventions were
performed in 195 patients, of which 15 patients received
thrombolysis more than once (1 patient, 6 times; 2 pa-
tients, 4; 2 patients, 3; and 10 patients, 2 times). Throm-
bolysis was administered to 87 patients (40 men, 47
women) registered in the municipality of Malmö. The
overall incidence of thrombolysis in Malmö due to lower
limb ischemia was estimated to be 6.6 (95% CI, 5.2-8.0)
per 100,000 person-years. The incidence for men and
women was 6.2 (95% CI, 4.3-8.2) and 6.9 (95% CI, 4.9-
8.8) per 100,000 person-years, respectively. The highest
incidence rates per 100,000 person-years were found in the
age category 75 to 84 years; overall, 41.8 (95% CI, 28.7-
54.8); men, 50.9 (95% CI, 27.4-74.3); and women, 36.2
(95% CI, 20.7-51.7).
Patients. The median age in the study population was
73 years (IQR, 62-80 years), with 75 years for women and
71 years for men (P  .10). The burden of cardiovascular
risk factors in the study patients are listed in detail in Table I.
Table I. Patient characteristics and comorbidities
Variable No. (%) or mean (IQR)
Age, years 73 (62-80)
Sex
Male 118 (54)
Female 102 (46)
Comorbidity
Hypertension 166/218 (76)
Smoking 143/191 (75)
Diabetes mellitus 49/220 (22)
Ischemic heart disease 74/219 (34)
Cerebrovascular disease 39/219 (18)
Atrial fibrillation 68/218 (31)
Anemia 63/210 (30)
Renal insufficiency 84/213 (39)
Medication
	-Adrenoceptor antagonists 72/219 (33)
ACE inhibitors 45/219 (21)
Lipid-lowering agents 71/219 (32)
Antiplatelet drugs 123/219 (56)
Warfarin 35/220 (16)
ACE, Angiotensin-converting enzyme; IQR, interquartile range.In all, 123 patients at admission were receiving antiplateletdrug therapy, including acetylsalicylic acid in 109, clopi-
dogrel in 21, and dipyridamole in one. Vascular disease
other than peripheral arterial insufficiency in the legs was
found in 167 of 220 patients (76%).
Symptoms and clinical findings at admission. The
median time from onset of symptoms to start of thrombol-
ysis was 67 hours for patients with acute leg ischemia and
144 hours for those with nonacute leg ischemia (P .001).
In patients with acute leg ischemia, symptom duration was
58 hours in patients with motor deficit and 72 hours in
those without motor deficit (P .47). Patients with diabe-
tes mellitus had a higher prevalence of foot ulcer (29% [14
of 48]) compared with all study patients (P  .001). The
spectrums of clinical findings are summarized in Table II.
Nature of the occlusions. Duplex ultrasound (DUS),
and MR and CT angiographies were performed in 28% (61
of 218), 10% (22 of 220), and 3% (7 of 220), respectively,
of the patients before thrombolysis. In patients with leg
ischemia andmotor deficit, DUS andCT angiography were
performed in 10 and two cases, respectively. The nature of
the acute occlusions is reported in Table III. Acute throm-
boembolic occlusions in native vessels occurred in 139
cases and were located in the infrarenal aorta in 2, common
iliac artery in 9, external iliac artery in 9, common femoral
artery in 12, profunda femoral artery in 7, superficial fem-
oral artery in 45, popliteal artery in 45, tibioperoneal trunk
in 2, anterior tibial artery in 5, peroneal artery in 1, and
posterior tibial artery in 2.
Thrombolysis. The median duration of thrombolysis
was 19 hours (IQR, 16-31 hours) in case of thrombosis and
20 hours (IQR, 14-33 hours) for embolus (P  .89). Six
patients received thrombolysis for 48 hours. The median
dosage of alteplase was 21.2 mg (IQR, 16.0-29.0 mg) in
case of thrombosis and 18.9 mg (IQR, 13.8-26.1 mg) for
embolus (P  .14). According to the radiologists’ descrip-
tions and conclusions at completion angiogram, 80% (170
of 213) of the thrombolysis succeeded in complete or
partial lysis (Table III). Regional thrombolysis with the
Table II. Symptoms and clinical findings before
thrombolysis
Variable Total No. No (%) or mean (IRQ)
Symptoms
Previous claudication 208 112 (54)
Symptom duration, hours
All 197 72 (26-168)
Acute ischemia 160 67 (24-149)
Nonacute ischemia 31 144 (48-744)
Clinical findings
Foot ulcer 218 27 (12)
Heel ulcer 218 8 (4)
Motor deficit 192 44 (23)
Sensory deficit 193 108 (56)
ABPI index 174 0.0 (0.0-0.26)
Acute ischemia 212 167 (79)
ABPI, Ankle-brachial pressure index; IQR, interquartile range.help of the heart–lung machine was performed in three
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due to popliteal aneurysm was followed by successful by-
pass operations in 11 cases. Diabetes mellitus was associ-
ated with a lesser degree of lysis (P .002). The quantity of
complementary procedures to thrombolysis is specified in
Table III. In all, endovascular treatment without need for
open surgery was performed in 167 cases (76%).
Complications and early failures of thrombolysis.
During thrombolysis, two patients died, respectively, of
cerebral hemorrhage and acute myocardial infarction. It
was not possible to complete the thrombolytic treatment as
planned in four patients due to unavailable beds at the ICU.
The frequency of bleeding complications was 33%, but only
13 of 220 (6%) thrombolysis resulted in premature inter-
ruption of ongoing treatment. In 66 patients (30%), no or
insufficient effect of the endovascular treatment resulted in
open surgery in 38, in-hospital amputation in 25, and three
deaths at the ICU after leg ischemia without any comple-
mentary action taken. The duration of thrombolysis (P 
.30) and the dosage of heparin (P  .43) were not associ-
ated with bleeding complications, whereas the dosage of
alteplase (P .041) was related to bleeding complications.
Factors associatedwith amputationduring follow-up.
Median follow-up was 32 months, during which 57 of 216
(26%) thrombolysis resulted in amputation of the ischemic
leg. The amputations were above knee in 19, ex-articulation
of the knee in 5, below knee in 27, and toe in 6. In 12
patients, a reamputation at a higher level was required,
resulting in amputations above the knee in 7, ex-articulation
of the knee in 1, below the knee in 3, and metatarsal in 1.
Table III. Nature of the occlusions and thrombolysis
characteristics
Variable
Total
No.
No. (%) or mean
(IRQ)
Etiology 220
Embolus 61
Thrombus 148
Uncertain 11
Occluded venous graft 219 9 (4)
Occluded synthetic graft 219 58 (26)
Occluded stent/stent graft 217 15 (7)
Popliteal aneurysm 218 15 (7)
Thrombolysis
Duration, hours 212 20 (16-32)
Dosage of alteplase, mg 211 20.5 (15.7-28.6)
Dosage of heparin, IU 198 19400 (13900-26800)
Degree of lysis
Complete lysis 213 88 (41)
Partial lysis 213 82 (38)
No lysis 213 30 (14)
Lysis, but no run-off 213 13 (6)
Ad mortem 220 2 (1)
Supplementary interventions 220 164 (75)
Open 29
Endovascular 112
Hybrid 23
IQR, Interquartile range.Duration of symptoms was not associated with amputation(P  .60). There was no difference in amputation rate at
end of follow-up in 59 patients with suprainguinal vs 159
with infrainguinal arterial occlusion (P  .10).
Factors associated with amputation were motor deficit
(P  .001), degree of lysis (P  .001), diabetes mellitus
(P .001), presence of foot ulcers (P .001), thrombotic
occlusion (P  .002), sensory deficit (P  .004), ischemic
heart disease (P .007), female gender (P .008), anemia
(P  .012), fasciotomy in the lower leg due to compart-
ment syndrome (P  .018), and renal insufficiency (P 
.02; Table IV). When these 11 variables were included in a
multivariate Cox regression analysis, degree of lysis (HR,
4.8; 95% CI, 2.4-9.7; P  .001), motor deficit (HR, 4.0;
95% CI, 1.8-8.7; P  .001), presence of foot ulcer (HR,
7.2; 95% CI, 2.2-23.4; P  .001), and ischemic heart
disease (HR, 2.3; 95% CI, 1.1-4.8l; P .024;) remained as
independent factors associated with amputation.
At time of admission to the hospital, themedian level of
C-reactive protein (CRP) was 26 mg/L in 53 patients who
underwent amputation compared with 9mg/L in 129 who
did not (P .001). The highest concentration of lactate in
plasma registered per patient (lactate max) during throm-
bolysis was not associated with amputation (P  .10).
Hemorrhagic complication during thrombolysis was re-
lated to a lower amputation rate (P .027). Fig 1 illustrates
amputation-free survival.
Factors associated with in-hospital mortality.
There were 11 in-hospital deaths. Factors associated with
in-hospital mortality after testing the 22 variables stated in
Tables IV to VI were degree of lysis (P  .001), renal
insufficiency (P  .007), cerebrovascular disease (P 
.014), andmotor deficit (P .036).When all four variables
were included in a multivariate Cox regression analysis,
degree of lysis (HR, 1.2; 95% CI, 2.7-63.8; P  .001) and
renal insufficiency (HR, 5.4; 95% CI, 1.1-26.6; P  .039)
remained as independent factors associated with death.
Factors associated with death during follow-up. In
all, 77 of 219 patients (35%) died during follow-up. In 31
thrombolysis (14%), lower limb ischemia was considered
either as primary or contributory cause of death. According
to death certificates, 40 patients (53%) died as a conse-
quence of cardiovascular event, and six patients died of lung
cancer. Duration of symptoms was not associated with
mortality (P  .20). There was no difference in the mor-
tality rate at end of follow-up in 59 patients with suprain-
guinal vs 159 with infrainguinal arterial occlusion (P 
.60). Factors associated with mortality during follow-up
were ischemic heart disease (P .001), motor deficit (P
.003), age 80 years (P  .003), acute ischemia (P 
.007), renal insufficiency (P  .008), cerebrovascular dis-
ease (P  .008), medication with warfarin (P  .010) and
presence of foot ulcers (P  .027; Table V).
When all eight variables were included in a multivariate
Cox regression analysis, renal insufficiency (HR, 2.4; 95%
CI, 1.4-4.2; P  .003), ischemic heart disease (HR, 2.1;
95% CI, 1.2-3.7; P  .007), cerebrovascular disease (HR,
2.2; 95% CI, 1.2-4.0; P  .009), presence of foot ulcer
20 (4
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(HR, 3.4; 95% CI, 1.1-10.1; P  .028) remained as inde-
pendent factors associated with mortality.
At time of admission to the hospital, themedian level of
CRP was 25 mg/L in 62 patients who subsequently died
during follow-up vs 9 mg/L in 119 who survived (P 
.001). Lactate max in patients who died was 1.3 mmol/L in
Table IV. Factors associated with amputation during follo
Factor Proportio
All thrombolysis 2
Comorbidity
Age  80 years 64/2
Woman 102/2
Diabetes mellitus 49/2
Ischemic heart disease 74/2
Warfarin 35/2
Cerebrovascular disease 39/2
Anemia 63/2
Renal insufficiency 83/2
Degree of ischemia
Foot ulcer 27/2
Motor deficit 44/1
Sensory deficit 107/1
Acute ischemia 166/2
Etiology
Thrombosis 148/2
Native artery occlusion 139/2
Occluded venous graft 9/2
Occluded synthetic graft 58/2
Popliteal aneurysm 15/2
Degree of lysis
Complete lysis 88/2
Partial lysis 82/2
Lysis, but no run-off 13/2
No lysis 30/2
Complementary interventions 164/2
Complications
Bleeding 72/2
Distal embolization 26/2
Fasciotomy (compartment syndrome) 9/2
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Fig 1. Amputation-free survival after thrombolysis for lower limb
ischemia. Numbers below time axis denote patients at risk at the
respective time point. The tick marks indicate censored data.64 compared with 1.1 mmol/L in 131 of those who did not(P .027). Amputation was associated with higher mortality
rate (P .005). Fig 2 illustrates long-term survival.
Factors associated with late adverse outcome in
terms of either amputation or death. The amputation-
free survival rate during follow-up was 51% (111 of 217).
When the 11 variables associated with either amputation or
mortality, in the univariate analysis (Table VI), were in-
p after thrombolysis
. (%) Amputation, No. (%) P
57/216 (26)
9) 13/62 (21) .25
6) 35/100 (35) .008
2) 23/49 (47) .001
4) 27/72 (38) .007
6) 13/35 (37) .12
8) 12/39 (31) .46
0) 23/62 (37) .013
9) 28/81 (35) .02
2) 14/27 (52) .001
3) 24/44 (55) .001
5) 36/106 (34) .004
8) 43/164 (26) .88
1) 47/145 (32) .002
3) 35/135 (26) .80
) 3/9 (33) .64
6) 19/57 (33) .17
) 5/14 (36) .42
1) 14/88 (16)
8) 15/79 (19)
) 9/13 (69)
4) 16/29 (55) .001
5) 43/161 (27) .86
3) 12/71 (17) .027
2) 5/25 (20) .44
) 5/8 (62) .018
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Fig 2. Long-time survival after thrombolysis for lower limb isch-
emia. Numbers below time axis denotes patients at risk at respec-
tive time point. The tick marks indicate censored data.w-u
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(HR, 2.5; 95% CI, 1.5-4.1; P  .001), renal insufficiency
(HR, 2.4; 95% CI, 1.5-4.04; P  .001), ischemic heart
disease (HR, 2.1; 95% CI, 1.3-3.4; P  .003), and foot
ulcers (HR, 3.2; 95% CI, 1.4-7.2; P  .005) remained as
independent factors for late adverse outcome.
DISCUSSION
This large study population allowed evaluation of im-
portant factors associated with amputation and mortality
during follow-up in patients receiving thrombolysis for
lower limb ischemia. Ischemic heart disease was shown to
be an independent risk factor for both amputation and
mortality. The presence of ischemic heart disease may be
seen as a marker for advanced generalized atherosclerosis,
and its strong association with peripheral arterial occlusive
disease is well documented.11 In fact, to reduce the mor-
tality rates after planned leg revascularization, it has been
proposed to perform coronary angiography and subse-
quent myocardial revascularization in severe surgically cor-
rectable coronary artery disease before arterial reconstruc-
tions due to lower limb ischemia.12 However, a better
medical treatment and clearance of risk factors such as
smoking13 are of greater importance and more feasible in
reducing manifestations of atherosclerotic disease in almost
Table V. Factors associated with mortality during follow-
Factor Proportion, N
All thrombolysis 220
Comorbidity
Age  80 years 64/220 (
Woman 102/220 (
Diabetes mellitus 49/220 (
Ischemic heart disease 74/219 (
Cerebrovascular disease 39/218 (
Warfarin 35/220 (
Anemia 63/210 (
Renal insufficiency 83/213 (
Degree of ischemia
Foot ulcer 28/218 (
Motor deficit 44/192 (
Sensory deficit 107/193 (
Acute ischemia 166/212 (
Etiology
Thrombosis 148/209 (
Native artery occlusion 139/219 (
Occluded venous graft 9/219 (
Occluded synthetic graft 58/219 (
Popliteal aneurysm 15/218 (
Degree of lysis
Complete lysis 88/213 (
Partial lysis 82/213 (
Lysis, but no run-off 13/213 (
No lysis 30/213 (
Complementary interventions 164/220 (
Complications
Bleeding 72/220 (
Distal embolization 26/220 (
Fasciotomya 9/220 (
aCompartment syndrome.all patients. The present study showed, in similarity withother studies,14 that there was a clear underuse of antiplate-
let and lipid-lowering agents before admission among pa-
tients with lower limb ischemia and signs of general athero-
sclerosis.
The two main adverse events, amputation and death,
have different risk factors associated with both early9 and, as
the present study has shown, late outcome after thrombol-
ysis. Risk factor analysis is very seldom matched against a
follow-up period longer than 1 year, and, in particular,
long-term data on leg salvage are scarce. The reported limb
salvage rate of 82% in one study15 and up to 88% in other
studies9,16 at 1 year is within the range of our results,
whereas the Kaplan-Meier curve in the present study shows
a continuous decline towards a limb salvage rate of only
60% at 5 years. Motor deficit and presence of foot ulcer at
admission, as well as degree of lysis, were independent
factors associated with amputation, which is in accordance
with the findings by Earnshaw et al.9 The amputation rate
among patients with diabetes mellitus receiving thrombol-
ysis was as high as 47%, which seems to be highly associated
with a lesser degree of lysis and the high prevalence of foot
ulcers among diabetic patients. Hence, diabetic patients
who have poor run-off and foot ulcers seem to be unsuit-
able candidates for thrombolysis.
The patients with motor deficit at admission need an
ter thrombolysis
) Death, No. (%) P
77/219 (35)
32/64 (50) .003
35/101 (35) .88
18/49 (37) .79
37/74 (50) .001
21/39 (54) .008
19/35 (54) .010
25/63 (41) .40
38/83 (48) .008
15/28 (54) .027
23/44 (52) .003
41/107 (38) .068
65/166 (40) .007
46/146 (32) .15
45/138 (33) .27
3/9 (33) .90
24/57 (42) .21
2/14 (15) .089
31/88 (35)
25/82 (30)
3/13 (23)
14/29 (48) .28
55/163 (34) .45
25/71 (35) .99
9/26 (35) .95
1/9 (11) .12up af
o. (%
29)
46)
22)
34)
18)
16)
30)
39)
13)
23)
55)
78)
71)
63)
4)
26)
7)
41)
38)
6)
14)
75)
33)
12)
4)urgent treatment either with thrombolysis or open revas-
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severe lower limb ischemia in patients with motor deficit,
witnesses of both a patient delay and a rather slow work-up,
may reflect logistic organizational problems such as un-
available beds in the ICU for the purpose of thrombolysis
or insufficient operative resources for surgical intervention.
Physician-caused delay was also identified, in that some
patients with motor deficit were referred for inappropriate
diagnostic imaging such as DUS and CT angiography
studies before thrombolysis. The high-resolution CT and
MR capabilities that are increasingly available are very use-
ful and comfortable tools for physicians, if timely used, to
outline the best treatment option for the patient. However,
there is a risk to exaggerate the value of these imaging
modalities and to further postpone treatment in patients
with already severely compromised peripheral circulation.
In patients with motor deficit, it may be better to operate
on the patient immediately17 and to perform an initial
on-table angiogram instead of pursuing with diagnostic
examination and late administration of thrombolysis. In
addition, the present study showed that 24% of the throm-
bolytic events needed to be supplemented with open vas-
cular surgery.
Interestingly, occurrence of bleeding complications
Table VI. Factors associated with late adverse outcome in
after thrombolysis
Factor Proportion, No. (%)
All thrombolysis 220
Comorbidity
Age  80 years 64/220 (29)
Woman 102/220 (46)
Diabetes mellitus 49/220 (22)
Ischemic heart disease 74/219 (34)
Cerebrovascular disease 39/218 (18)
Warfarin 35/220 (16)
Anemia 63/210 (30)
Renal insufficiency 83/213 (39)
Degree of ischemia
Foot ulcer 28/218 (13)
Motor deficit 44/192 (23)
Sensory deficit 107/193 (55)
Acute ischemia 166/212 (78)
Etiology
Thrombosis 148/209 (71)
Native artery occlusion 139/219 (63)
Occluded venous graft 9/219 (4)
Occluded synthetic graft 58/219 (26)
Popliteal aneurysm 15/218 (7)
Degree of lysis
Complete lysis 88/213 (41)
Partial lysis 82/213 (38)
Lysis, but no run-off 13/213 (6)
No lysis 30/213 (14)
Complementary interventions 164/220 (75)
Complications
Bleeding 72/220 (33)
Distal embolization 26/220 (12)
Fasciotomya 9/220 (4)
aCompartment syndrome.during thrombolysis was associated with lower amputationrates in the present study. The occurrence of minor bleed-
ing episodes, locally or distant, should not automatically
equal discontinuation of thrombolysis. Hence, it may be
important to accept minor bleeding complications during
thrombolysis to be able to achieve the best possible limb
perfusion and to prevent some amputations. Another cen-
ter has reported a higher bleeding complication rate with a
high-dose regimen of rt-PA, compared with our study, but
was able to achieve a successful thrombolysis in 86% of the
limbs.18 Even though high-dose bolus therapy of rt-PA
seems to accelerate thrombolysis without compromising
outcome,19 the risk of bleeding must be weighed against
the risk of surgery in each patient.20
Renal insufficiency was a strong factor associated with
death after thrombolysis in the present study. The admin-
istration of a contrast agent during angiographies may be a
negative factor in this subgroup of patients. However, renal
insufficiency is also clearly associated with poorer outcome
in patients after open vascular surgery.21 In addition, war-
farin treatment was also associated with increasedmortality,
probably due to an increased burden of cardiovascular
illnesses among these patients.
The limitations of the present study are attributed to its
retrospective design. In a few patients, it was not possible to
s of either amputation or mortality during follow-up
Amputation or death, No. (%) P
106/217 (49)
38/62 (61) .020
53/100 (53) .26
31/49 (63) .022
49/73 (67) .001
27/39 (69) .004
24/35 (69) .011
39/62 (63) .009
54/83 (65) .001
21/27 (78) .001
33/44 (75) .001
57/106 (54) .021
85/165 (52) .13
70/146 (48) .96
65/136 (48) .62
4/9 (44) .78
33/58 (57) .16
6/14 (43) .63
35/88 (40)
35/80 (44)
10/13 (77)
20/29 (69) .003
81/162 (50) .56
31/71 (44) .29
12/26 (46) .77
6/9 (67) .28termdetermine whether a patient had acute lower limb ischemia
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tations may still be underestimated, even though we ac-
tively searched for available amputation data, because in-
hospital registers for this variable are often deficient.22
CONCLUSION
Thrombolysis is often successful, with few major com-
plications in most patients with lower limb ischemia. Pa-
tients with ischemic heart disease and foot ulcers are at
higher long-term risk for both amputation and death. A
lesser degree of lysis and motor deficit were associated with
higher amputation rates. The presence of such negative
prognostic factors may help clinicians to deny further inva-
sive vascular treatment. Renal insufficiency, cerebrovascular
disease, and acute lower limb ischemia were associated with
increased mortality.
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